What to Do When Cigna Denies Zepbound: Step-by-Step Appeal
Introduction
Cigna runs pharmacy benefits through Express Scripts, which means Zepbound® denials come back as Express Scripts adverse determination letters. The level-1 appeal goes to Express Scripts first, not directly to Cigna.
The denial reasons cluster around six issues: prior authorization criteria not met, step therapy requiring Wegovy® or older agents first, BMI below threshold, weight-loss drug carve-out by the employer, OSA criteria missing for the sleep apnea indication, and incomplete documentation of a structured weight management program. Each has a specific counter that can be submitted on appeal.
CMS data from 2023 puts the overturn rate at roughly 41 percent for commercial denials when patients file a level-1 internal appeal with new clinical documentation. Zepbound appeals have an additional lever in 2026: the FDA approved Zepbound for moderate to severe obstructive sleep apnea in December 2024, based on SURMOUNT-OSA. That OSA indication is a separate pathway with relaxed criteria on most Cigna plans.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
Why Does Cigna Deny Zepbound?
Six denial codes account for roughly 90 percent of Cigna Zepbound rejections. The codes are PA-NOT-MET, NF (non-formulary), STEP-REQ (step therapy required, often Wegovy first), BMI-NOT-MET, EMP-EXCL (employer carve-out), and OSA-DOCS-MISSING (when applying under the OSA indication).
Quick Answer: Cigna processes Zepbound through Express Scripts; level-1 appeals go to Express Scripts first
Pull your Express Scripts adverse determination letter and find the reason code. The wording is near a phrase reading “reason for adverse determination.” The appeal strategy depends on which code applies.
A step therapy requirement for Wegovy first creates a paradox if your plan denied Wegovy too. The workaround is a medical necessity exception citing prescriber preference for the SURMOUNT-1 trial outcomes (Jastreboff et al. 2022, NEJM) showing 20.9 percent weight loss at 72 weeks with tirzepatide, versus 14.9 percent with semaglutide in STEP 1 (Wilding et al. 2021, NEJM).
What Is Cigna’s 2026 Prior Authorization for Zepbound?
Cigna’s 2026 commercial PA for Zepbound requires five things: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity.
Some Cigna plans add a step therapy requirement for Wegovy or an older agent first. The step requirement can be waived with documented contraindication, intolerance, or insufficient response.
For the obstructive sleep apnea indication added after SURMOUNT-OSA in December 2024, criteria are different. The PA requires confirmed AHI of 15 or higher on polysomnography and BMI of 30 or higher. The 6-month lifestyle program requirement is typically waived under the OSA pathway.
How Do I File a Level-1 Internal Appeal for Zepbound?
You have 180 days from the denial date to file a level-1 internal appeal. The submission goes to Express Scripts at the address on the denial letter, usually a PO Box in St. Louis, Missouri.
The appeal packet should include a signed appeal letter from you, a Letter of Medical Necessity signed by your prescriber, chart notes from the past 12 months, BMI and weight history, documentation of the 6-month weight management program, and prior medication trials with dates and outcomes. If you’re applying under the OSA indication, include the polysomnography report and AHI data.
Express Scripts has 30 days to respond on a standard appeal and 72 hours on an expedited appeal. Expedited appeals require prescriber attestation that delay would seriously jeopardize health. Reasonable triggers include uncontrolled type 2 diabetes, established CVD, or severe OSA with documented daytime symptoms.
What Should the Letter of Medical Necessity Say?
The LMN is the single most important document. It should be on prescriber letterhead, signed and dated, and limited to two pages. Express Scripts reviewers spend about 6 minutes per file on average.
Hit five points directly. First, current BMI and weight, plus BMI trend over 24 months. Second, every comorbidity that meets Cigna criteria with ICD-10 codes. Third, prior weight-loss interventions with dates and outcomes, including any prior GLP-1 trials, phentermine, Contrave, Qsymia, or commercial programs. Fourth, clinical rationale citing the SURMOUNT-1 trial (Jastreboff et al. 2022, NEJM) showing 20.9 percent weight loss at 72 weeks, SURMOUNT-2 (Garvey et al. 2023, Lancet) for patients with type 2 diabetes, and SURMOUNT-OSA for the sleep apnea indication if applicable. Fifth, a statement that lifestyle modifications alone have not produced sustained clinical response.
A focused, two-page LMN outperforms a five-page one almost every time.
What Clinical Evidence Does Cigna Respect?
Express Scripts and Cigna’s P&T committee reference specific trials when updating coverage policy. Citing those trials by name puts your appeal in their internal language.
For Zepbound, the strongest 2026 references are SURMOUNT-1 (Jastreboff et al. 2022, NEJM) showing 20.9 percent weight loss at 72 weeks, SURMOUNT-2 (Garvey et al. 2023, Lancet) showing 15.7 percent weight loss in patients with type 2 diabetes, SURMOUNT-3 (Wadden et al. 2023, Nature Medicine) for the intensive behavioral therapy combination, SURMOUNT-4 for weight maintenance, and SURMOUNT-OSA for the sleep apnea indication.
Pick the two trials most relevant to your clinical situation. A focused appeal looks more credible than a literature dump.
Key Takeaway: The 2026 Cigna PA requires BMI of 30 or higher, or 27 with comorbidity, plus a 6-month documented weight management program
What If the First Appeal Is Denied?
You can file a level-2 internal appeal within 60 days of the level-1 denial, and pursue external review through your state commissioner in parallel.
The level-2 internal appeal at Cigna goes to a different reviewer, usually a board-certified physician. The packet can include the same documents plus a peer-to-peer review request, where your prescriber speaks directly with Cigna’s medical director. Peer-to-peer requests are typically granted and significantly improve overturn rates.
External review through your state insurance commissioner is independent and decisions are binding. The deadline is usually 4 months from the final internal denial. The IRO assigns a board-certified physician in endocrinology, obesity medicine, or pulmonology (for OSA cases). The review costs nothing. Approval rates at external review run around 50 percent for prescription drug denials.
How Does the OSA Indication Change the Appeal?
If you have moderate to severe obstructive sleep apnea with documented AHI of 15 or higher on polysomnography, the OSA indication is a separate appeal pathway with different criteria.
The FDA approved Zepbound for OSA in December 2024 after SURMOUNT-OSA showed significant AHI reduction in patients with moderate to severe OSA and obesity. The trial reduced AHI by about 27 events per hour in the treatment arm versus about 4 in placebo, and 43 percent of treatment-arm patients reached an AHI of 5 or fewer events per hour.
The LMN should explicitly state “requested for moderate-to-severe OSA per FDA-approved indication based on SURMOUNT-OSA.” Cite the polysomnography results. Most Cigna plans waive the 6-month lifestyle program requirement under the OSA pathway.
What If My Cigna Plan Carves Out Weight-loss Drugs?
This is the hardest denial to overturn because the benefit design comes from the employer, not Cigna’s medical policy. You have three practical options.
First, ask HR whether the carve-out applies to all indications or only the obesity indication. The OSA indication may be covered separately on self-funded plans because it is a respiratory disease benefit, not a weight-loss benefit. Second, request a formulary exception based on medical necessity with documented OSA, type 2 diabetes, or CVD. Third, consider cash-pay options. The Eli Lilly LillyDirect cash pharmacy offers Zepbound vials at $349 to $499 per month for commercially-insured patients without coverage and for cash-pay patients.
Compounded tirzepatide is no longer available through 503A pharmacies after the FDA resolved the tirzepatide shortage in late 2024. Compounded semaglutide remains a legal option through licensed telehealth providers like TrimRx, with a free assessment quiz determining eligibility.
How Long Does the Full Appeal Process Take?
A standard level-1 internal appeal takes 30 days. A level-2 takes another 30 days. External review is usually 45 days but can be expedited to 72 hours with documented urgent medical need.
Full timeline if you exhaust every level: roughly 4 to 5 months from initial denial to a final external review decision. Expedited appeals can compress this to 10 to 14 days.
During the appeal, options include paying cash with a plan for retroactive reimbursement if the appeal succeeds, using LillyDirect Zepbound vials at the cash-pay rate, or starting a personalized treatment plan with compounded semaglutide through a telehealth provider while the appeal is pending.
Bottom line: You have 180 days to file a level-1 internal appeal and 4 months for external review through your state commissioner
FAQ
Can I Appeal a Cigna Zepbound Denial Without My Doctor’s Help?
Possible but rare to succeed. The Letter of Medical Necessity from the prescriber carries clinical authority that a patient letter cannot match. Most prescribers will write an LMN if you provide the denial letter and ask in writing.
Does Cigna Cover Zepbound for Medicare Patients?
No, in most cases. Medicare Part D does not cover Zepbound for obesity as of 2026. CMS has not extended Medicare coverage to the obesity indication for tirzepatide. Zepbound may be covered under Part D for the OSA indication on certain Cigna Medicare Advantage plans that include the OSA rider, but this is plan-specific.
Does Cigna Require Wegovy STEP Therapy Before Zepbound?
Some Cigna plans require prior trial of Wegovy or another GLP-1 first. The step requirement can be waived with documented contraindication, intolerance, or insufficient response. A documented prior failure on Wegovy due to GI tolerability or insufficient weight loss after a full titration trial is the easiest waiver.
How Much Does Zepbound Cost with Cigna Coverage?
With PA approved on Tier 3, expect a copay of $40 to $100 per month for commercial plans. High-deductible plans charge the full negotiated rate (around $900 to $1,000) until the deductible is met. Without coverage, brand Zepbound lists at about $1,059 per month, with the LillyDirect direct-cash program running $349 to $499 per month for vials.
Can I Get an Expedited Appeal If I Have Severe OSA?
Yes. Severe OSA with documented AHI of 30 or higher, documented daytime sleepiness, or evidence of cardiovascular complications all support an expedited appeal request. Your prescriber must attest in writing that delay would jeopardize health.
What Documents Does Express Scripts Want in a Zepbound Appeal?
A signed appeal letter from you, a Letter of Medical Necessity from your prescriber, chart notes from the past 12 months, BMI and weight history, documentation of the 6-month weight management program, prior medication trials with dates, and (for the OSA pathway) a polysomnography report with AHI documentation.
Is There a Zepbound Savings Program Through Eli Lilly?
Yes. The Lilly Savings Card can bring eligible commercially-insured patients to as low as $25 per month for Zepbound pens for short periods. The LillyDirect direct-cash pharmacy offers Zepbound single-dose vials at $349 to $499 per month for cash-pay patients, available without insurance approval through a connected telehealth assessment.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
How to Maintain Weight Loss After Stopping Zepbound
Stopping Zepbound is a significant decision, and the period immediately after is when the strategies you put in place matter most. The biology of…
What Happens After You Reach Your Goal Weight on Zepbound?
Reaching your goal weight on Zepbound is a significant milestone, and it raises a question that doesn’t get enough attention during the early stages…
Zepbound Withdrawal Symptoms: What to Expect Off the Drug
Zepbound does not cause physical withdrawal the way opioids or benzodiazepines do.
